Incubator Resident Clients

Applied Food Technologies, Inc.
is a growth stage biotechnology company developing molecular diagnostics to address issues related to safety, science and technology in the food industry. Current efforts are focused primarily on the domestic and international seafood industry. AFT was the first to develop DNA based diagnostics for use in the seafood industry for species identification and verification. A recent increase in awareness and prevention by seafood importers, distributors, and large retail establishments has increased AFT's fee-for-service testing work-flow. AFT is now preparing for rapid growth.
Contact:
LeeAnn Applewhite, CEO, 386.418.3661

www.appliedfoodtechnologies.com

Learn more about AFT

AxoGen, Inc. is a biomedical company developing products that will allow surgeons to repair and regenerate peripheral nerves more successfully than ever before.  Every year in the US, several million people suffer peripheral nerve injuries, a major source of disability that impairs the ability to move muscles or to feel normal sensations.  AxoGen, utilizing a seasoned management team with a strong track record, is revolutionizing peripheral nerve procedures based on scientific breakthroughs that reveal the mechanism of axon growth and regeneration.
Contact:
Karen Zaderej, CEO, 386.462.6800

www.axogeninc.com

Learn more about AxoGen

Banyan Biomarkers, Inc.  is developing novel biomarker diagnostic and therapeutic products to address unmet clinical needs associated with organ injury.  Our initial diagnostic products will be for the detection and monitoring of traumatic brain injury (TBI).  No simple, point-of-care blood test currently exists to detect the presence and severity of brain trauma.  Detecting biomarkers associated with TBI will provide rapid indications of brain trauma essential for earlier intervention and management.  Banyan’s therapy development program focuses on a compound that will block two enzymes which cause additional brain cell death following the initial damage to the brain tissue.  By blocking the action of these enzymes, subsequent tissue damage can be reduced or even eliminated, thus improving patient outcomes.  Banyan’s ongoing research is performed in the company’s Center of Innovative Research (CoIR) which is a unique self-supporting research infrastructure focused on developing a pipeline of novel products for both diagnostic and therapeutic uses.  Banyan also provides analytical laboratory services to pharmaceutical companies looking to evaluate candidate drug compounds that may produce neurotoxicity or neuroprotection. 
Contact:
Dr. Jackson Streeter, CEO and CMO, 386.462.6699

www.banyanbio.com

Learn more about Banyan

EigenChem Technologies, Inc. is a concept-stage start-up company developing disruptive technologies for the cleantech and biotech business sectors. The company will capitalize upon novel approaches to making quantum dots for energy and biomedical applications, advanced photochemical solar cells, and turning large-scale polymeric wastes into value-added products.
Contact:
Polina Oliferenko, CEO, 352.792.4008

Pasteuria Bioscience, Inc. is an early-stage agricultural biotechnology company formed to address the world’s largest unmet pest-control problem: plant-parasitic nematodes.  Our proprietary technology allows the in-vitro growth and sporulation of Pasteuria penetrans, a naturally-occurring nematode pathogen, for nematode control in crops ranging from high-value ornamentals to agronomic staples. 
Contact:
Al Kern, Executive Chairman, 386.462.0008

www.pasteuriabio.com